Danish biomarker company Nordic Bioscience announced on Friday nordicEndotrophin, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrophin signalling hormone-qualified in the CAP/CLIA certified Nordic Bioscience laboratory.
Alongside the company's existing product line, the assay demonstrated prognostic utility in fibrosis and cancer studies.
NordicEndotrophin joins nordicPRO-C6 and nordicPRO-C3 (in-house versions of the FDA-supported PRO-C6 and CE approved PRO-C3 assays) to deliver a one-stop solution for assessing the fibro-inflammatory axis in chronic diseases, including cardiovascular, metabolic and renal. Following PRO-C3's recent deployment on Roche IVD platforms, the new Endotrophin assay strengthens risk stratification and pharmacodynamic monitoring, Nordic Bioscience said.
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Amgen offers Repatha through AmgenNow direct-to-patient programme
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
Abbott's Navitor TAVI system granted CE Mark for expanded indication
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
OptiBiotix signs distribution deal with major weight management company
Novartis to present cardiovascular abstracts portfolio data at ESC Congress in Madrid